Eubelius advises Calliditas Therapeutics in connection with proposed acquisition of Genkyotex SA
Calliditas Therapeutics, a Swedish specialty pharmaceutical company listed on Nasdaq Stockholm and on the Nasdaq Global Select Market, has entered into an agreement to acquire a controlling interest of 62.7% in Genkyotex SA, a French biopharmaceutical company, leading in NOX therapies, listed on Euronext Paris and Euronext Brussels.
Calliditas is seeking to acquire all outstanding Genkyotex shares and, following completion of the control transaction, which is expected to close in October 2020, will launch a mandatory cash tender offer in France and Belgium on the same terms for the remaining shares.
Latham & Watkins LLP, Vinge and Eubelius are acting as legal advisers to Calliditas in the global transaction. The Eubelius team, which includes Marieke Wyckaert, Joris De Wolf and Simon Flament, is advising Calliditas in connection with the Belgian law aspects of the tender offer.